Yee CSK, et al. - Researchers examined children with reactivity to ≤50mg peanut protein and with high peanut-IgE (median 229 kU/L) for whom omalizumab was successfully used to facilitate peanut oral immunotherapy (OIT). The goal was to describe long-term OIT outcomes in these patients, including dosing changes, adverse events, peanut immunoglobulin changes and quality of life (QoL). They found that quicker and effective desensitization was achieved with adjunctive omalizumab in patients with high peanut-IgE, but it induced reactions that led to the discontinuation of OIT within 72 months in almost half of patients. They observed higher month 12 peanut-IgE and Arah2-IgE among those who ceased therapy. Longer omalizumab administration in these patients might be beneficial.